First report of Penicillium costaricense Visagie, M. Urb & Seifert (Eurotiales, Ascomycota) in South America and a second report for the world

Penicillium costaricense was isolated in air samples from a surgery center in a public hospital in Brazil. The only published data on the occurrence of this species is from caterpillar intestine of Rothschildia lebeau in Costa Rica. The isolate was identified by morphology together with the molecular markers β-tubulin and calmodulin. This report is a warning call to understand the pathogenicity of this species. To the best of our knowledge, this is the first report of P. costaricense in South American and the second in the world

First report of Penicillium costaricense Visagie, M. Urb & Seifert (Eurotiales, Ascomycota) in South America and a second report for the world

Penicillium costaricense was isolated in air samples from a surgery center in a public hospital in Brazil. The only published data on the occurrence of this species is from caterpillar intestine of Rothschildia lebeau in Costa Rica. The isolate was identified by morphology together with the molecular markers β-tubulin and calmodulin. This report is a warning call to understand the pathogenicity of this species. To the best of our knowledge, this is the first report of P. costaricense in South American and the second in the world

First record of Aspergillus hongkongensis C.C. Tsang et al. (Eurotiales, Ascomycota) in South America and the third report worldwide

The genus Aspergillus P. Micheli is among the most abundant fungi worldwide. Numerous species belonging to this genus have been reported to contaminate food and cause infections. We isolated Aspergillus hongkongensis C.C. Tsang et al. from eggplant flour sold in Recife, Brazil. The isolate was identified using morphological and molecular analyses (beta-tubulin and calmodulin genes). This is the first record of A. hongkongensis in South America and the third report worldwide. Our study contributes to a better understanding of the phenotypic variations in this species, as well as the geographic distribution of Aspergillus species

Coexistence of T-Large Granular Lymphocyte Leukemia and Peripheral T Cell Lymphoma-NOS with Indolent Behavior

T-cell lymphomas and leukemias are highly heterogeneous groups of rare disorders. We report a case of a 68-year-old man patient who developed two different T-cell neoplasms (Large Granular Lymphocyte Leukemia [LGLL] in 2018 and Peripheral T-cell non-Hodgkin lymphoma not otherwise specified [PTCL-NOS] in 2019) with a previous diagnosis of B-cell marginal zone lymphoma in 2010, treated with two lines of chemo-immunotherapy. The coexistence of these different T-cell neoplasms is rarely reported in the literature. Moreover, it is usually described as an LGLL transformation into PTCL-NOS; differently from these examples, herein, the simultaneous conditions appear to be driven by different T-cell clones. Furthermore, the PTCL-NOS had quite unusual behavior, with good disease control without intensive treatment. Because of these features, it could belong to a subgroup of indolent PTCL-NOS, not yet described in the WHO classification of T-cell neoplasms, which could benefit from less aggressive treatment

Antimicrobial and enzymatic activity of anemophilous fungi of a public university in Brazil

<div><p>ABSTRACT To the fungal microbiota the UFPE and biotechnological potential enzymatic and antimicrobial production. Air conditioned environments were sampled using a passive sedimentation technique, the air I ratio and the presence of aflatoxigenic strains evaluated for ANVISA. Icelles were to determine the enzymatic activity of lipase, amylase and protease metabolic liquids to determine antimicrobial activity. Diversity was observed in all CAV environments, CFU/m3 ranged from 14 to 290 and I/E ratio from 0.1 to 1.5. The of the fungal genera were: Aspergillus (50%), Penicillium (21%), Talaromyces (14%), Curvularia and Paecilomyces (7% each). Aspergillus sydowii (Bainier & Sartory) Thom & Church presented enzymatic activity and the Talaromyces purpureogenus Samson, Yilmaz, Houbraken, Spierenb., Seifert, Peterson, Varga & Frisvad presented antibacterial activity against all bacteria that all environments present fungal species biodiversity no toxigenic or pathogenic fungi were found, according to ANVISA legislation for conditioned environments and airborne filamentous fungi present potential for enzymatic and antimicrobial activity.</p></div

Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort

: Although chronic lymphocytic leukemia (CLL) predominantly affects the elderly, limited data exists about the outcomes of over 80-year-old patients, usually underrepresented in clinical trials. we conducted a multicenter study enrolling 79 consecutive CLL patients ≥80&nbsp;years at the time of frontline therapy, all treated with ibrutinib. nearly 48% of cases exhibited unmutated IGHV genes, 32% 17p deletion, and 39.2% TP53 mutations; 63.3% displayed a cumulative illness rating scale (CIRS)&nbsp;&gt;&nbsp;6. the overall response rate on ibrutinib, computed in 74/79 patients (5 patients excluded for early withdrawal), was 89.9%. after a median follow-up of 28.9&nbsp;months, the median progression-free survival (PFS) and overall survival (OS) were 42.5 and 51.8&nbsp;months, respectively. CIRS&gt;6 and temporary discontinuation of ibrutinib lasting for 7-30&nbsp;days were the only parameters associated with a significantly shorter PFS and were both relevant in predicting a shorter PFS compared to patients with CIRS≤6 and therapy discontinuation ≤7&nbsp;days. The most common grade≥3 adverse events were infections (25.5%), neutropenia (10.1%), and anemia (2.5%). eighteen patients (22.8%) experienced a cardiovascular event, including grade-2 atrial fibrillation (n&nbsp;=&nbsp;9; 11%), grade-2 hypertension (n&nbsp;=&nbsp;5; 6%), heart failure (n&nbsp;=&nbsp;3; 3%), and acute coronary syndrome (n&nbsp;=&nbsp;1; 1%). mild bleeding events were observed in 27 patients (34.2%). Ibrutinib was permanently discontinued in 26 patients due to progressive disease (n&nbsp;=&nbsp;11, including 5 Richter's syndromes), secondary malignancies (n&nbsp;=&nbsp;6), infections (n&nbsp;=&nbsp;3), cardiac failure (n&nbsp;=&nbsp;3), severe bleeding (n&nbsp;=&nbsp;2), and sudden death (n&nbsp;=&nbsp;1). In conclusion, our analyses confirmed the overall effectiveness and favorable safety profile of the ibrutinib-single agent therapeutic approach in CLL patients ≥80&nbsp;years